Last reviewed · How we verify
BB102
At a glance
| Generic name | BB102 |
|---|---|
| Also known as | BB102 |
| Sponsor | Broadenbio Ltd., Co. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma (PHASE2)
- A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BB102 CI brief — competitive landscape report
- BB102 updates RSS · CI watch RSS
- Broadenbio Ltd., Co. portfolio CI